Loading...

Indivior PLC

INDV.L•LSE
HealthcareDrug Manufacturers - Specialty & Generic
$844.50
$19.00(2.30%)

Indivior PLC (INDV.L) Stock Overview

Explore Indivior PLC’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
8.69%
↑ 8.69%
Profit Growth
$0.02
EPS Growth
$0.02
↑ 36.99%
Operating Margin
2.90%
↑ 900.00%
ROE
-1.30%
Dividend Yield
0.00%
Analyst Recommendations data is not available for INDV.LAnalyst Recommendations details for INDV.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

CEO

Mr. Ryan Preblick

Employees

1,030

Headquarters

10710 Midlothian Turnpike, North Chesterfield, VA

Founded

2014

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.